Products for Research Use Only

LY2334737

CAT: 0804-HY-13672-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13672-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects[1][2].
CAS Number
892128-60-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Enterovirus; Nucleoside Antimetabolite/Analog
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/ly2334737.html
Purity
98.55
Solubility
DMSO : ≥ 100 mg/mL
Smiles
OC[C@@H]1[C@H](C(F)(F)[C@H](N2C(N=C(C=C2)NC(C(CCC)CCC)=O)=O)O1)O
Molecular Formula
C17H25F2N3O5
Molecular Weight
389.39
Precautions
H302, H315, H319, H335
References & Citations
[1]Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19 (5) :1159-68.|[2]Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11 (3) :680-9.|[3]Jialei Sun, et al. Drug Repurposing of Pyrimidine Analogs as Potent Antiviral Compounds Against Human Enterovirus A71 Infection With Potential Clinical Applications. Sci Rep. 2020 May 18;10 (1) :8159.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1